Positive Results for Guselkumab for Moderate PsO Patients

Guselkumab treatment resulted in clear or almost clear skin in the majority of adults with low body surface area (BSA) moderate plaque psoriasis (PsO) with special site involvement who had failed topical treatment, according to data presented at the 44th Annual Fall Clinical Dermatology Conference.

The Phase 3b SPECTREM study was the first prospective, large-scale, randomized-controlled, double-blind clinical study to measure skin clearance and other treatment outcomes in low BSA moderate PsO with involvement across four special sites (scalp, face, skin folds and genitals) and previous topical treatment failure, according to Johnson & Johnson, which developed guselkumab under the brand name TREMFYA.

“Results of the SPECTREM study could represent a new approach to care for patients with low body surface area psoriasis, as the majority of patients treated with TREMFYA achieved clear or almost clear skin,” study investigator Linda Stein Gold, MD, said.

A significantly greater proportion of patients who received TREMFYA® achieved the primary endpoint of an Investigator’s Global Assessment (IGA) score of cleared (0) or minimal disease (1) compared to those who received placebo (74.2% versus 12.4%, respectively; p<0.001). These results were comparable irrespective of baseline BSA.

The overall safety in the SPECTREM study was consistent with the established TREMFYA® safety profile.